Haemophilia R&D Portfolio
Novo Nordisk began research and development in haemophilia over 20 years ago to improve the treatment of haemophilia patients with inhibitors. These efforts culminated in the successful launch of NovoSeven® in 1996, which was a significant treatment innovation in this area. NovoSeven® remains the only recombinant treatment approved for this indication today.
Since then, Novo Nordisk has applied its expertise in protein science and technology to build a broad pipeline of projects aimed at improving treatment for all people with haemophilia, while also increasing their access to care.
Changing possibilities in haemophilia®
Novo Nordisk aspires for leadership in haemophilia and the Haemophilia R&D Portfolio area drives pipeline projects that address unmet treatment needs for the full spectrum of haemophilia conditions, as well as other rare bleeding disorders.
Currently, we are working to develop two potential successors to NovoSeven®: A long-acting recombinant factor VIIa derivative and a fast-acting recombinant factor VIIa analogue, both of which are in clinical development.
We are also leveraging our core protein science and technology capabilities to develop recombinant factor XIII for people who are deficient of this factor and a factor VIII, as well as long-acting factor VIII and IX compounds for the treatment of haemophilia A and B, respectively.
Global operations back haemophilia expansion
Our global haemophilia trials are listed at our clinical trials website. To ensure best practice, skills and knowledge in the development of haemophilia therapies, as well as effective recruitment of patients to our ongoing clinical trials in this area, we work with the world’s leading academic centres and preferred industrial partners.
Our clinical trials are conducted out of our regional Clinical Medical Regulatory offices covering North America, Europe, Japan, China and the rest of the world, respectively. People participating in Novo Nordisk trials are protected by the same rights, high ethical standards and regulations irrespective of the location of the trial, as the same procedures are applied in all trials all over the world.
